OPTIMAL HYPOGLYCEMIC THERAPY IN PATIENTS WITH DIABETES MELLITUS AND CHRONIC HEART FAILURE: MODERN RECOMMENDATIONS
Abstract
The review discusses the problem of increased risk of chronic heart failure in patients with diabetes mellitus. Currently, diabetes is considered as an independent factor in the development of cardiovascular catastrophes. Convincing results of large randomized long-term multicenter studies to reduce the risk of cardiovascular events in patients with diabetes mellitus on the background of optimally selected effective hypoglycemic therapy are presented: EMPA-REG OUTCOME (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients-Removing Excess Glucose) and DEСLARE – TIMI 58 (Dapagliflozin Effect on CardiovascuLAR Events). A new class of innovative hypoglycemic drugs with insulin-independent mechanism of action – inhibitors of sodium-glucose cotransporter type 2 – is discussed. Glycemic and non-glycemic pharmacological effects of this group of drugs are studied in detail. Great attention is drawn to cardioprotective and nephroprotective properties of these drugs. The latest recommendations of the American Diabetes Association / European Association for the Study of Diabetes, and the Russian Association of Endocrinologists (Standards of Specialized Diabetes Care, 2019) on personalizing the choice of hypoglycemic drugs in patients with diabetes and chronic heart failure are discussed.
References
1. Алгоритмы специализированной медицинской помощи больным сахарным диабетом / Под редакцией И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. – 9-й выпуск (дополненный). – М.; 2019. DOI: 10.14341/DM221S1.
2. Bailey C., Gross J., Hennicken D. et al. Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial // BMC Med. – 2013. – Vol. 11. – P. 43.
3. Baker W.L., Smyth L.R., Riche D.M. et al. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis // Am. Soc. Hypertens. – 2014. – Vol. 8, № 4. – Р. 269–275.
4. Bolinder J., Ljunggren O., Kullberg J. et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin // J. Clin. Endocrinol. Metab. – 2012. – Vol. 97. – Р. 1020–1031.
5. Davies M.Y., Alessio D.A., Fradkin J. et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). EASD, ADA 2018 // Diabetes Care. - 2018. – Vol. 41. – P. 2669–701. DOI: 10.2337/dci18-003.
6. Ferrannini E., Mark M., Mayoux E. CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis // Diabetes Care. – 2016. – Vol. 39(7). – P. 1108-1114. doi: 10.2337/dc16-0330
7. Ferrannini G., Hach T., Crowe S. et al. Energy balance after sodium-glucose cotransporter 2 inhibition // Diabetes Care. – 2015. – Vol. 38, № 9. – Р. 1730–1735.
8. Filippatos T., Elisaf M. High density lipoprotein and cardiovascular diseases // World J. Cardiol. – 2013. – Vol. 5. – P. 210–214.
9. Fonseca V.A. Ongoing clinical trials evaluating the cardiovascular safety and efficacy of therapeutic approaches to diabetes mellitus // Am J. Cardiol. - 2011. – Vol. 108(3 Suppl). – P.52B-8B.
10. Giaccari A., Sorice G., Muscogiuri G. Glucose toxicity: the leading actor in the pathogenesis and clinical history of type 2 diabetes – mechanisms and potentials for treatment // Nutr. Metab. Cardiovasc. Dis. – 2009. – Vol.19, № 5. – Р. 365–377.
11. Greenberg B.H., Abraham W.T., Albert N.M., Chiswell K., Clare R., Stough W.G., Gheorghiade M., O'Connor C.M., Sun J.L., Yancy C.W., Young J.B., Fonarow G.C. Influence of diabetes on characteristics and outcomes in patients hospitalized with heart failure: a report from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). // Am Heart J. – 2007. – Vol. 154. – P. 277–278.
12. He J., Ogden L.G., Bazzano L.A. et al. Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study // Arch Intern Med. - 2001. - № 161. - Р. 996-1002.
13. Hoeben E., De Winter W., Neyens M., Devineni D. et al. // Clin. Pharmacokinet. – 2016, Feb. – Vol. 55, № 2. – Р .209-223.
14. Kalra S., Singh V., Nagrale D. Sodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A Review // Adv Ther. – 2016. – V. 33(9). – P. 1502-1518. doi: 10.1007/s12325-016-0379-5.
15. Кannel W.B., Hjortland M., Castelli W.P. Role of diabetes in congestive heart failure: the Framingham study // Am J. Cardiol. – 1974. – Vol. 34. – P. 29–3411
16. Kannel W.B., McGee D.L. Diabetes and cardiovascular disease. The Framingham study // JAMA. – 1979. – Vol. 241. – Vol. 2035–2038.
17. Lambers Heerspink H., Zeeuw De, Wie L. et al Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes // Diabetes Obes. Metab. – 2013. – Vol. 15. – P. 853–862.
18. Lombardi C., Spigoni V., Gorga E., Dei Cas A. Novel insight into the dangerous connection between diabetes and heart failure // Herz.- 2016 May. – Vol. 41(3). – Р. 201-7. doi: 10.1007/s00059-016-4415-7.
19. Lopaschuk G.D., Verma S. Empagliflozin’s fuel hypothesis: not so soon // Cell. Metab. – 2016. – Vol. 24, №2. – Р. 200–202.
20. Neal B., Perkovic V., Mahaffey K.W. et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes // N. Engl. J. Med. – 2017, Jun 12; Epub.
21. Perkovic V., de Zeeuw D., Mahaffey K.W., Fulcher G., Erondu N., Shaw W., Barrett T.D., Weidner-Wells M., Deng H., Matthews D.R., Neal B. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials // Lancet Diabetes Endocrinol. - 2018 Sep. – Vol. 6(9). – P. 691-704. doi: 10.1016/S2213-8587(18)30141-4. Epub 2018 Jun 21.
22. Rajeev S.P., Cuthbertson D.J., Wilding J.P. Energy balance and metabolic changes with sodium-glucose co-transporter 2 inhibition // Diabetes Obes. Metab. – 2016. – Vol.18, №2. – Р.125–134.
23. Sahasrabudhe V., Terra S.G., Fountaine R.J. et al. The effect of renal impairment on the pharmacokinetics and pharmacodynamics of ertugliflozin in subjects with type 2 diabetes mellitus / Poster presented at: EASD 2015 51st European Association for the Study of Diabetes; September 14, 2015; Stockholm, Sweden.
24. Saleem F. Dapagliflozin: Cardiovascular Safety and Benefits in Type 2 Diabetes Mellitus // Cureus. – 2017, Oct 5. – Vol. 9. - № 10. – Р. 1751.
25. Scheen A.J., Paquot N. Metabolic effects of SGLT-2 inhibitors beyond increased glucosuria: a review of the clinical evidence // Diabetes Metab. – 2014. – Vol. 40(6 Suppl 1). – P. 4–11.
26. Seifalian A., Filippatos T., Joshi J., Mikhailidis D. Obesity and arterial compliance alterations // Curr. Vasc. Pharmacol.- 2010. – Vol. 8. – P. 155–168.
27. Sha S. D., Polidori T. et al. Effect of the sodium glucose co transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus // Diabetes Obes. Metab. – 2014. – Vol.16, № 11. – Р. 1087–1095.
28. Shah N., Deeb W., Choksi R., Epstein B. Dapagliflozin: a novel sodium-glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitus // Pharmacotherapy. – 2012. – Vol. 32. – P. 80–94.
29. Terami N., Ogawa D., Tachibana H., Hatanaka T. et al. Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice / PLoS One. - 2014 Jun 24. – Vol. 9(6)/ -e100777. doi: 10.1371/journal.pone.0100777. eCollection 2014.
30. Wiviott S.D., Raz I., Bonaca M.P., et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes // N Engl J. Med. - 2018 Nov 10. https://doi.org/10.1056/NEJMoa1812389. [Epub ahead of print].
31. Zinman B., Wanner C., Lachin J.M., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes// N Engl. J. Med. - 2015. – Vol. 373. – P. 2117–28.
2. Bailey C., Gross J., Hennicken D. et al. Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial // BMC Med. – 2013. – Vol. 11. – P. 43.
3. Baker W.L., Smyth L.R., Riche D.M. et al. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis // Am. Soc. Hypertens. – 2014. – Vol. 8, № 4. – Р. 269–275.
4. Bolinder J., Ljunggren O., Kullberg J. et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin // J. Clin. Endocrinol. Metab. – 2012. – Vol. 97. – Р. 1020–1031.
5. Davies M.Y., Alessio D.A., Fradkin J. et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). EASD, ADA 2018 // Diabetes Care. - 2018. – Vol. 41. – P. 2669–701. DOI: 10.2337/dci18-003.
6. Ferrannini E., Mark M., Mayoux E. CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis // Diabetes Care. – 2016. – Vol. 39(7). – P. 1108-1114. doi: 10.2337/dc16-0330
7. Ferrannini G., Hach T., Crowe S. et al. Energy balance after sodium-glucose cotransporter 2 inhibition // Diabetes Care. – 2015. – Vol. 38, № 9. – Р. 1730–1735.
8. Filippatos T., Elisaf M. High density lipoprotein and cardiovascular diseases // World J. Cardiol. – 2013. – Vol. 5. – P. 210–214.
9. Fonseca V.A. Ongoing clinical trials evaluating the cardiovascular safety and efficacy of therapeutic approaches to diabetes mellitus // Am J. Cardiol. - 2011. – Vol. 108(3 Suppl). – P.52B-8B.
10. Giaccari A., Sorice G., Muscogiuri G. Glucose toxicity: the leading actor in the pathogenesis and clinical history of type 2 diabetes – mechanisms and potentials for treatment // Nutr. Metab. Cardiovasc. Dis. – 2009. – Vol.19, № 5. – Р. 365–377.
11. Greenberg B.H., Abraham W.T., Albert N.M., Chiswell K., Clare R., Stough W.G., Gheorghiade M., O'Connor C.M., Sun J.L., Yancy C.W., Young J.B., Fonarow G.C. Influence of diabetes on characteristics and outcomes in patients hospitalized with heart failure: a report from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). // Am Heart J. – 2007. – Vol. 154. – P. 277–278.
12. He J., Ogden L.G., Bazzano L.A. et al. Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study // Arch Intern Med. - 2001. - № 161. - Р. 996-1002.
13. Hoeben E., De Winter W., Neyens M., Devineni D. et al. // Clin. Pharmacokinet. – 2016, Feb. – Vol. 55, № 2. – Р .209-223.
14. Kalra S., Singh V., Nagrale D. Sodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A Review // Adv Ther. – 2016. – V. 33(9). – P. 1502-1518. doi: 10.1007/s12325-016-0379-5.
15. Кannel W.B., Hjortland M., Castelli W.P. Role of diabetes in congestive heart failure: the Framingham study // Am J. Cardiol. – 1974. – Vol. 34. – P. 29–3411
16. Kannel W.B., McGee D.L. Diabetes and cardiovascular disease. The Framingham study // JAMA. – 1979. – Vol. 241. – Vol. 2035–2038.
17. Lambers Heerspink H., Zeeuw De, Wie L. et al Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes // Diabetes Obes. Metab. – 2013. – Vol. 15. – P. 853–862.
18. Lombardi C., Spigoni V., Gorga E., Dei Cas A. Novel insight into the dangerous connection between diabetes and heart failure // Herz.- 2016 May. – Vol. 41(3). – Р. 201-7. doi: 10.1007/s00059-016-4415-7.
19. Lopaschuk G.D., Verma S. Empagliflozin’s fuel hypothesis: not so soon // Cell. Metab. – 2016. – Vol. 24, №2. – Р. 200–202.
20. Neal B., Perkovic V., Mahaffey K.W. et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes // N. Engl. J. Med. – 2017, Jun 12; Epub.
21. Perkovic V., de Zeeuw D., Mahaffey K.W., Fulcher G., Erondu N., Shaw W., Barrett T.D., Weidner-Wells M., Deng H., Matthews D.R., Neal B. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials // Lancet Diabetes Endocrinol. - 2018 Sep. – Vol. 6(9). – P. 691-704. doi: 10.1016/S2213-8587(18)30141-4. Epub 2018 Jun 21.
22. Rajeev S.P., Cuthbertson D.J., Wilding J.P. Energy balance and metabolic changes with sodium-glucose co-transporter 2 inhibition // Diabetes Obes. Metab. – 2016. – Vol.18, №2. – Р.125–134.
23. Sahasrabudhe V., Terra S.G., Fountaine R.J. et al. The effect of renal impairment on the pharmacokinetics and pharmacodynamics of ertugliflozin in subjects with type 2 diabetes mellitus / Poster presented at: EASD 2015 51st European Association for the Study of Diabetes; September 14, 2015; Stockholm, Sweden.
24. Saleem F. Dapagliflozin: Cardiovascular Safety and Benefits in Type 2 Diabetes Mellitus // Cureus. – 2017, Oct 5. – Vol. 9. - № 10. – Р. 1751.
25. Scheen A.J., Paquot N. Metabolic effects of SGLT-2 inhibitors beyond increased glucosuria: a review of the clinical evidence // Diabetes Metab. – 2014. – Vol. 40(6 Suppl 1). – P. 4–11.
26. Seifalian A., Filippatos T., Joshi J., Mikhailidis D. Obesity and arterial compliance alterations // Curr. Vasc. Pharmacol.- 2010. – Vol. 8. – P. 155–168.
27. Sha S. D., Polidori T. et al. Effect of the sodium glucose co transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus // Diabetes Obes. Metab. – 2014. – Vol.16, № 11. – Р. 1087–1095.
28. Shah N., Deeb W., Choksi R., Epstein B. Dapagliflozin: a novel sodium-glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitus // Pharmacotherapy. – 2012. – Vol. 32. – P. 80–94.
29. Terami N., Ogawa D., Tachibana H., Hatanaka T. et al. Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice / PLoS One. - 2014 Jun 24. – Vol. 9(6)/ -e100777. doi: 10.1371/journal.pone.0100777. eCollection 2014.
30. Wiviott S.D., Raz I., Bonaca M.P., et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes // N Engl J. Med. - 2018 Nov 10. https://doi.org/10.1056/NEJMoa1812389. [Epub ahead of print].
31. Zinman B., Wanner C., Lachin J.M., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes// N Engl. J. Med. - 2015. – Vol. 373. – P. 2117–28.
Published
2019-12-01
How to Cite
ХАМНУЕВА, Лариса Юрьевна; ХАНТАКОВА, Екатерина Александровна; СЕРГЕЕВНА, Андреева Лариса.
OPTIMAL HYPOGLYCEMIC THERAPY IN PATIENTS WITH DIABETES MELLITUS AND CHRONIC HEART FAILURE: MODERN RECOMMENDATIONS.
Sibirskij Medicinskij Zurnal (Irkutsk) = Siberian Medical Journal (Irkutsk) 16+, [S.l.], v. 159, n. 4, p. 5-9, dec. 2019.
ISSN 1815-7572. Available at: <http://smj.ismu.baikal.ru/index.php/osn/article/view/384>. Date accessed: 01 jan. 2026.
Issue
Section
Scientific reviews
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
